Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.41 |
| ▸ | KDM5A | P29375 | 4/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.41 |
| ▸ | KDM4A | O75164 | 2/20 | 0.41 |
| ▸ | QPCT | Q16769 | 6/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 2/20 | 0.37 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.36 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13604735 | 0.77 | QPCT (0.46) | KDM4CKDM5AKDM5BKDM4AQPCT | |
| SCHEMBL13604330 | 0.74 | KDM4C (0.43) | KDM4CKDM5AKDM5BKDM4AQPCT | |
| SCHEMBL6763115 | 0.73 | HSD17B10 (0.46) | QPCT | |
| SCHEMBL22180834 | 0.71 | QPCT (0.38) | KDM4CKDM5AKDM5BKDM4AQPCT | |
| SCHEMBL2157361 | 0.71 | TSHR (0.50) | QPCTALPLPLAAALPG | |
| SCHEMBL1178918 | 0.70 | — | — | |
| SCHEMBL6992439 | 0.70 | QPCT (0.40) | QPCTALPLPLAAALPG | |
| SCHEMBL31251980 | 0.69 | QPCT (0.48) | QPCTALPLPLAAALPG | |
| SCHEMBL4483111 | 0.69 | TSHR (0.42) | QPCTSIGMAR1 | |
| Bromide SCHEMBL6375209 | 0.69 | ALPL (0.41) | QPCTALPLPLAAALPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1833481-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION | 2006-09-21 | — | — | US | disclosed |
| WO-2006065794-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | FNTB, FNTA, FDPS | KDM4C 4148/4885KDM5A 4099/4885KDM5B 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.